Conduct↦Quality and Risk↦Regulatory Inspections↦Findings
What is it? Why is it important?
Findings mean that given audit/inspection criteria were not met. Findings occur as a result of a process and/or system deficiency, where audit/inspection evidence do not comply with audit/inspection criteria.
In studies, typical audit/inspection criteria include:
- The EC approved study protocol
- Study relevant SOPs
- ICH GCP, ISO Guidelines (e.g. ISO 14155)
- The law (e.g. Swiss law)
In studies, typical evidence include:
- Essential documents in TMF/ISF
- Signed and dated ICF
- IMP/IMD handling
- Safety reporting procedures
- Evidence can also originate from staff interviews
Findings are categorised based on the severity of non-compliance and include the 3 categories, namely minor, major, and critical according to EMA`s grading of inspection findings. Main focus is any non-compliance that jeopardizes the safety of study participants and the quality of study data.
More
Based in the European Medicine Agency (EMA) findings that are not-met are categorised – as follows:
Critical:
- Condition, practices or processes that adversely affect the rights, safety or well-being of the subjects and/or the quality and integrity of data
- Critical observations are considered totally unacceptable
- Possible consequences: rejection of data and/or legal action required
- Observations classified as critical may include a pattern of deviations classified as major
Major:
- Condition, practices or processes that might adversely affect the rights, safety or well-being of the subjects and/or the quality and integrity of data
- Major observations are severe deficiencies and are direct violations of GCP principles
- Possible consequences: data may be rejected and/or legal action required
- Observation classified as major may include a pattern of deviations and/or numerous minor observations
Minor:
- Condition, practices or processes that would not be expected to adversely affect the rights, safety or well-being of the subjects and/or the quality and integrity of data.
- Possible consequences: observations classified as minor indicate the need for improvement of conditions, practices and processes.
- Many minor observations may indicate poor quality and the sum might be equal to a major finding with its consequences.
What do I need to do?
Findings must be subject to a root-cause analysis. This mean that:
- Findings must be corrected in order to return to criteria compliance
- Corrective actions must be defined in order to prevent the reoccurrence of finding(s) (e.g. risk management)
- The SP-INV submits a CAPA plan to inspectors that describes the management of findings, including a timeline for their resolution. A priority should be given to critical or major findings.
Based on the outcome of the inspection, the SP-INV is responsible to submit a CAPA plan to the inspectors and ensure the CAPA plan is implemented according to defined timelines.
More
Example of a finding
The participant signed the document 2 days prior to the Site-INV. Participant and Site-INV did not date and sign the ICF on the same day.
Criteria: Participant and Site-INV must jointly date and sign the ICF during the visit when the participant is informed - and included in the study.
Route cause analysis: Participants receive study information including the ICF document to take home for evaluation. Upon return to the clinic participants have already signed the ICF. The Site-INV is not aware of the requirement that the ICF must be jointly signed on the same day.
Preventive action: Training of Site-INV regarding joint signing criteria. ICF process was adapted. In the event the participant has pre-dated and signed the ICF he/she will re-sign on the day of study inclusion together with the Site-INV.
Where can I get help?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
References
ICH GCP E6(R2) – see in particular guidelines
- 1.29 Inspection
- 1.6 Audit
- 5.0 Quality management
ISO 9001 (access liable to costs) – see in particular section
- QMS Requirements
ISO 19011 (access liable to costs) – see in particular section
- Guidelines for auditing management systems
EMA – see in particular document
Procedure for reporting of GCP inspections requested by the committee for Medical Products for Human Use (CHMP)
- Appendix 5: Grading of inspection findings
Swiss Law
ClinO – see in particular articles
- Art. 46 Agency inspections